1Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. The Lancet 358:1389-1399 (2001).
2Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, et al. (2006) Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin–cohort study in Ontario, Canada. Journal of the National Cancer Institute 98:1694-1706.
3Robson ME, Boyd J, Borgen PI, Cody HS (2001) Hereditary breast cancer. Current Problems in Surgery. 38:387-480.
4Rubin SC, Blackwood MA, Bandera C, Behbakht K, Benjamin I, Rebbeck TR, et al. (1998) BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. American Journal of Obstetrics and Gynecology 178:670-677.
5Whittemore AS, Gong G, Itnyre J (1997) Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three US population-based case-control studies of ovarian cancer. American Journal of Human Genetics 60:496.
6Roa BB, Boyd AA, Volcik K, Richards CS (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nature Genetics 14:185.
7Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. Journal of Clinical Oncology 25:1329-1333.
8Kuchenbaecker KB, Hopper JL, Barnes DR, Philips KA, MooijTM, et al. (2005) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 294:1925.
9Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al. (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. Journal of the National Cancer Institute 105:812-822.
10American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstetrics and Gynecology 113:957 (2009).
11National Comprehensive Cancer Network (2018) Genetic/familial high-risk assessment: breast and ovarian. NCCN clinical practice guidelines in oncology 1.
12Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, et al. (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292:1317-1325.
13Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, et al. (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. New England Journal of Medicine 351:427-437.
14Skytte AB, Crüger D, Gerster M, Laenkholm AV, Lang C, et al. (2011) Breast cancer after bilateral risk‐reducing mastectomy. Clinical Genetics 79:431-437.
15Nelson HD, Pappas M, Zakher B, Mitchell JP, Okinaka-Hu L, Fu R. (2014) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the US Preventive Services Task Force recommendation. Annals of Internal Medicine 160:255-266.
16Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, et al. (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304:967-975.
17Davidson BA, Moorman PG (2014) Risk–benefit assessment of the combined oral contraceptive pill in women with a family history of female cancer. Expert opinion on drug safety 13:1375-82.
18Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, et al. (2006) Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 296:185-192.
19Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. (2007) Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. The American Journal of Surgical Pathology 31:161-169.
20Kwon JS, Tinker A, Pansegrau G, McAlpine J, Housty M, et al. ( 2013) Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstetrics & Gynecology 121:14-24.
21Finch A, Evans G, Narod SA (2012) BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations. Women’s Health 8:543-55.
22Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertility and Sterility 98:1407-1415 (2012).
23Scully R, Livingston DM (2000) In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 408:429-432.
24Jackson SP, Bartek J (2009) The DNA-damage response in human biology and disease. Nature 461:1071-1078.
25Titus S, Li F, Stobezki R, Akula K, Unsal E, et al. (2013) Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Science Translational Medicine 5:172ra121-172ra121.
26Jazayeri A, Falck J, Lukas C, Bartek J, Smith GCM, Lukas J, et al. (2006) ATM-and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nature Cell Biology 8:37-45.
27Tronov VA, Loginova MJ, Kramarenko II (2008) Methylnitrosourea as challenge mutagen in assessment of the DNA mismatch repair (MMR) activity: association with some types of cancer. Russian Journal of Genetics 44:595-600.
28Xiong B, Li S, Ai J-S, Yin S, et al. (2008) BRCA1 is required for meiotic spindle assembly and spindle assembly checkpoint activation in mouse oocytes. Biology of Reproduction 79:718-726.
29Sekhon L, Rodriguez-Purata J, Lee J, Whitehouse M (2016) Ovarian reserve and embryonic aneuploidy rates in BRCA 1 and 2 carriers. Fertility and Sterility 106:e371.
30d’Estaing SG, Perrin D, Lenoir GM, Guérin JF, Dante R (2005) Upregulation of the BRCA1 gene in human germ cells and in preimplantation embryos. Fertility and Sterility 84:785-788.
31Hakem R, de la Pompa JL, Sirard C, Mo R, Woo M, et al. (1996) The tumor suppressor gene BRCA1 is required for embryonic cellular proliferation in the mouse Cell 85:1009-1023.
32Gal I, Sadetzki S, Gershoni-Baruch R, Oberman B, Carp H, et al. (2004) Offspring gender ratio and the rate of recurrent spontaneous miscarriages in Jewish women at high risk for breast/ovarian cancer. The American Journal of Human Genetic 74:1270-1275.
33Lin WT, Beattie M, Chen L-M, Oktay K, Crawford SL, Gold EB, et al. (2013) Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non–clinic‐based sample of women in northern California. Cancer 119:1652-1659
34Finch A, Valentini A, Greenblatt E, Lynch HT, Ghadirian P, et al. (2013) Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertility and Sterility 99:1724-1728.
35Michaelson-Cohen R, Mor P, Srebnik N, Beller U, Levy-Lahad E, et al. (2014) BRCA mutation carriers do not have compromised ovarian reserve. International Journal of Gynecological Cancer 24:233-237.
36Wang ET, Pisarska MD, Bresee C, Chen Y-DI, Lester J, Afshar Y, et al. (2014) BRCA1 germline mutations may be associated with reduced ovarian reserve. Fertility and Sterility 102:1723-1728.
37Phillips K-A, Collins IM, Milne RL, McLachlan SA, Friedlander M, et al. (2016) Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations. Human Reproduction dew044.
38Johnson L, Sammel MD, Domchek S, Schanne A, Prewitt M, et al. (2017) Antimüllerian hormone levels are lower in BRCA2 mutation carriers. Fertility and Sterility 107:1256-
39Oktay K, Kim JY, Barad D, Babayev SN (2010) Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. Journal of Clinical Oncology 28:240-244.
40Derks-Smeets IA, van Tilborg TC, van Montfoort A, Smits L, Torrance HL, Meijer-Hoogeveen M, et al. (2017) BRCA1 mutation carriers have a lower number of mature oocytes after ovarian stimulation for IVF/PGD. Journal of Assisted Reproduction and Genetics 1-8.
41Shapira M, Raanani H, Feldman B, Srebnik N, Dereck-Haim S, Manela D, et al. (2015) BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles. Fertility and Sterility 104:1162-1167.
42Lin W, Titus S, Moy F, Ginsburg ES, Oktay K (2017) Ovarian Aging in Women With. The Journal of Clinical Endocrinology & Metabolism 102:3839-47.
43Ormondroyd E, Donnelly L, Moynihan C, Savona C, et al. (2012) Attitudes to reproductive genetic testing in women who had a positive BRCA test before having children: a qualitative analysis. European Journal of Human Genetics 20:4-10.
44Schover LR (2009) Patient attitudes toward fertility preservation. Pediatric Blood &Cancer 53:281-284.
45Practice Committee of the American Society for Reproductive Medicine, and Practice Committee of the Society for Assisted Reproductive Technology.Ovarian tissue and oocyte cryopreservation. Fertility and Sterility 90:S241-S246 (2008).
46Oktay K, Cil AP, Bang H (2006) Efficiency of oocyte cryopreservation: a meta-analysis. Fertility and Sterility 86:70-80.
47(2009) Practice Committee of the American Society for Reproductive Medicine. ASRM Practice Committee response to Rybak and Lieman: elective self-donation of oocytes. Fertility and Sterility 92:1513-1514.
48Ethics Committee of the American Society for Reproductive Medicine. Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion. Fertility and Sterility 100:1224-1231 (2013).
49Wilkinson E (2012) Preimplantation genetic diagnosis for mutated BRCA genes. The Lancet Oncology 13:e331.
50Kim SS, Klemp J, Fabian C (2011) Breast cancer and fertility preservation. Fertility and Sterility 95:1535-1543.
51Hickey M, Peate M, Saunders C, Friedlander M (2009) Breast cancer in young women and its impact on reproductive function. Human Reproduction Update
52Quinn GP, Vadaparampil ST, Tollins S, Miree CA, Murphy D, et al. (2010) BRCA carriers' thoughts on risk management in relation to preimplantation genetic diagnosis and childbearing: when too many choices are just as difficult as none. Fertility and Sterility 94:2473-5.
53Kim J, Skrzynia C, Mersereau JE (2015) A pilot study of BRCA mutation carriers’ knowledge about the clinical impact of prophylactic-oophorectomy and views on fertility consultation: a single-center pilot study. Journal of Genetic Counseling 24:149-157.
54Staton AD, Kurian AW, Cobb K, Mills MA, Ford JM (2008) Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. Familial Cancer 7:179-186.
55Menon U, Harper J, Sharma A, Fraser L, Burnell M, ElMasry K, et al. (2007) Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer. Human Reproduction 22:1573-1577.
56Quinn G, Vadaparampil S, Wilson C, King L, Choi J, Miree C, et al. (2009) Attitudes of high-risk women toward preimplantation genetic diagnosis. Fertility and Sterility 91:2361-2368.
57Strømsvik N, Råheim M, Øyen N, Gjengedal E (2009) Men in the women’s world of hereditary breast and ovarian cancer—a systematic review. Familial Cancer 8:221-229.
58Derks-Smeets IA, Gietel-Habets JJ, Tibben A, Tjan-Heijnen VC, Meijer-Hoogeveen M, et al. (2014) Decision-making on preimplantation genetic diagnosis and prenatal diagnosis: a challenge for couples with hereditary breast and ovarian cancer. Human Reproduction 29:1103-12.
59Quinn GP, Pal T, Murphy D, Vadaparampil ST, Kumar A (2012) High-risk consumers' perceptions of preimplantation genetic diagnosis for hereditary cancers: a systematic review and meta-analysis. Genetics in medicine 14:191-200.
60Quinn GP, Vadaparampil ST, Bower B, Friedman S, Keefe DL (2009) Decisions and ethical issues among BRCA carriers and the use of preimplantation genetic diagnosis. Minerva medica 100:371-83.
61Quinn GP, Vadaparampil ST, King LM, Miree CA, Friedman S (2009) Conflict between values and technology: perceptions of preimplantation genetic diagnosis among women at increased risk for hereditary breast and ovarian cancer. Familial cancer 8:441-9.
62Gietel-Habets JJ, de Die-Smulders CE, Derks-Smeets IA, Tibben A, et al. (2017) Awareness and attitude regarding reproductive options of persons carrying a BRCA mutation and their partners. Human Reproduction 32:588-97.
63Brandt AC, Tschirgi ML, Ready KJ, Sun C, Darilek S, Hecht J, et al. (2010) Knowledge, attitudes, and clinical experience of physicians regarding preimplantation genetic diagnosis for hereditary cancer predisposition syndromes. Familial Cancer 9:479-487.
64Chan J, Johnson L, DiGiovanni L, Voong C, Sammel MD, et al. (2015) Reproductive decision-making in patients diagnosed with BRCA mutations. Fertility and Sterility 104:e76.
65Goodwin T, Elizabeth Oosterhuis B, Kiernan M, Hudson MM, Dahl GV (2007) Attitudes and practices of pediatric oncology providers regarding fertility issues. Pediatric Blood &Cancer 48:80-85.
66Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski J, Partridge AH, et al. (2013) Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology 31:2500-2510.
67Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. (2006) American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. Journal of Clinical Oncology 24:2917-2931.
68Treff NR, Scott RT Jr. (2013) Four-hour quantitative real-time polymerase chain reaction-based comprehensive chromosome screening and accumulating evidence of accuracy, safety, predictive value, and clinical evidence. Fertility and Sterility 99:1049-53.
69Werner M, Reh A, Grifo J, Perle MA (2012) Characteristics of chromosomal abnormalities diagnosed after spontaneous abortions in an infertile population. Journal of Assisted Reproduction and Genetics 29:817-820.
70Insogna IG, Ginsburg E (2016) Transferring embryos with indeterminate PGD results: the ethical implications. Fertility Research and Practice 2:2.
71Zreik TG, Mazloom A, Chen Y, Vannucci M, Pinnix CC, Fulton S, et al. (2010) Fertility drugs and the risk of breast cancer: a meta-analysis and review. Breast Cancer Research and Treatment 124:13-26
72van den Belt-Dusebout AW, Spaan M, Lambalk CB, Kortman M, Laven JSE, et al. (2016) Ovarian stimulation for in vitro fertilization and long-term risk of breast cancer. JAMA 316:300-312
73Kotsopoulos J, Librach CL, Lubinski J, Gronwald J, Kim-Sing C, Ghadirian P, et al. (2008) Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case–control study. Cancer Causes & Control 19:1111-1119.
74Kim J, Turan V, Oktay k (2016) Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer.The Journal of Clinical Endocrinology & Metabolism. 101:1364-1371.
75Rizzuto I, Behrens RF, Smith LA (2013) Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. The
Cochrane Library 8.
76Lerner‐geva L, Geva E, Lessing J, Chetrit A, Modan B, Amit A (2003) The possible association between in vitro fertilization treatments and cancer development. International Journal of Gynecological
77Bamford P, Steele S (1982) Uterine and ovarian carcinoma in a patient receiving gonadotrophin therapy. BJOG: An International
Journal of Obstetrics & Gynaecology 89:962-964.
78Rossing MA, Daling JR, Weiss NS, Moore DE (1994) Self SG. Ovarian tumors in a cohort of infertile women. New England Journal
of Medicine 331:771-776.
79Tazelaar HD, Bostwick DG, Ballon SC, Hendrickson MR, Kempson RL (1985) Conservative treatment of borderline ovarian tumors.
Obstetrics & Gynecology 66:417-422.
80Perri T, Lifshitz D, Sadetzki S, Oberman B, Meirow D, Ben-Baruch G, et al. (2015) Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers. Fertility and Sterility 103:1305-1312.
81Gronwald J, Glass K, Rosen B, Karlan B, Tung N, Neuhausen SL, et al. (2016) Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Fertility and Sterility 105:781-785.
82Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ, et al. (2002) Infertility, fertility drugs, and ovarian cancer:
a pooled analysis of case-control studies. American Journal of Epidemiology. 155:217-224.
83Beiner ME, Gotlieb WH, Davidson B, Kopolovic J, Ben‐Baruch G (2001) Infertility treatment after conservative management of borderline ovarian tumors. Cancer 92:320-325.
84Wallach EE, Shoham Z (1994) Epidemiology, etiology, and fertility drugs in ovarian epithelial carcinoma: where are we today? Fertility and Sterility 62:433-448.
85Van Leeuwen F, Klip H, Mooij T, van de Swaluw AMG, Lambalk CB, Kortman M, et al. (2011) Risk of borderline and invasive ovarian
tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Human Reproduction 322.
86Skirnisdottir I, Garmo H, Wilander E, Holmberg L (2008) Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and
age at diagnosis compared to ovarian cancer. International Journal of Cancer 123:1897.